Register for our free email digests:
Latest From Teijin Pharma Ltd.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2017.
In Vivo's editors pick May's most significant deals, including Thermo Fisher's bid for Patheon and Merck's tie-up with Teijin. (Free article.)
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
Following positive Phase II data from its CRTh2 antagonist PTR-36 in eosinophilic asthma patients, Pulmagen is looking for a late-stage development partner. PTR-36 is administered at a dose 'an order of magnitude lower' than a competing program from Novartis which is in Phase III, said the small UK firm.
- Medical Devices
- Specialty Pharmaceuticals
- Therapeutic Areas
- Eastern Europe
- Parent & Subsidiaries
- NovaMedica LLC
- Senior Management
Fabrice Egros, Deputy CEO & COO
Maria Makarova, CFO
Mikhail Getman, VP, R&D & Regulatory Affairs
Alojz Pungarsek, VP, Commercial, Sales & Mktg.
Mary Anderson, VP, Bus. Dev.
- Contact Info
Phone: 495 230 02 90
29, 1-st Brestskaya St.
Moscow, NJ 117036
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.